MedTrace Logo

Effects of Radioactive Iodine on the Immune System in Thyroid Cancer

NCT05989555 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2023-11-18

No results posted yet for this study

Summary

Blood will be drawn 1 month before and 2 month after regular radioactive iodine treatment. Monocytes will be isolated. The three main outcomes are whole blood counts, cytokine production upon in vitro stimulation of monocytes and in vitro ROS production by monocytes. These results are compared between patients treated in adjuvant setting and patients treated for persistent structural disease, and between pre- and post-treatment status.

Conditions

  • Thyroid Carcinoma, Nonmedullary

Interventions

OTHER

Blood drawing

Blood is drawn twice in all subjects. Once before treatment with radioacitve iodine and once after.

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2025-06-01
Completion
2025-12-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05989555 on ClinicalTrials.gov